乳腺癌随访和药物副作用管理策略的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.015

摘要/Abstract

摘要： 乳腺癌是全球女性发病率最高的恶性肿瘤,随着诊断技术及治疗手段的不断提高,乳腺癌患者接受系统治疗后生存期明显延长。乳腺癌患者需要长时间的随访以便及早监测到局部复发和远处转移。此外,激素敏感性乳腺癌患者还需要给予5~10年的内分泌治疗,针对其副作用的全程管理也需要随访,进而提高患者的生活质量,减轻患者疾病负担。本文就近年来乳腺癌随访相关方面进行简要综述。

关键词: 乳腺癌, 随访, 副作用管理, 心理支持

Abstract: Breast cancer is the malignant tumor with the highest incidence in women.With the continuous improvement of diagnostic technology and treatment methods,the survival period of breast cancer patients after receiving systemic therapy has been significantly prolonged.This requires long-term follow-up for early detection of local recurrence and distant metastasis.In addition,hormone-sensitive breast cancer also needs to be given endocrine therapy for 5~10 years,and the full management of side effects also requires follow-up,improve the quality of life of patients,and provide patients with physical and psychological support.This article makes a brief review on breast cancer follow-up related aspects in recent years.

Key words: Breast cancer, Follow-up, Side effects management, Psychological support

中图分类号:

R737.9

赵丹妮, 闫石, 蔡莉. 乳腺癌随访和药物副作用管理策略的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 369-373.

ZHAO Danni, YAN Shi, CAI Li. Research progress on follow - up and drug side effect management strategy of breast cancer[J]. Journal of Practical Oncology, 2022, 36(4): 369-373.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/369

参考文献

1 Ferlay J,Colombet M,Soerjomataram I,et al.Cancer statistics for the year 2020:An overview[J].Int J Cancer,2021,10:100.
2 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
3 Sopik V,Sun P,Narod SA.Predictors of time to death after distant recurrence in breast cancer patients[J].Breast Cancer Res Treat,2019,173(2):465-474.
4 马飞,徐兵河,邵志敏.乳腺癌随访及伴随疾病全方位管理指南[J].中华肿瘤杂志,2019,41(1):29-41.
5 Moy L,Bailey L,D Orsi C,et al.ACR appropriateness criteria stage I breast cancer:initial workup and surveillance for local recurrence and distant metastases in asymptomatic women[J].J Am Coll Radiol,2017,14(5):282-292.
6 Aarts A,Duffy SW,Geurts S,et al.Towards evidence-based follow-up intervals for breast cancer survivors:Estimates of the preclinical detectable phase of contralateral second breast cancer[J].Breast,2019,45:70-74.
7 Tsoutsou PG,Vozenin M,Durham A,et al.How could breast cancer molecular features contribute to locoregional treatment decision making?[J].Crit Rev Oncol Hematol,2017,110(110):43-48.
8 Sun YS,Zhao Z,Yang ZN,et al.Risk factors and preventions of breast cancer[J].Int J Biol Sci,2017,13(11):1387-1397.
9 Kozak MM,Jacobson CE,von Eyben R,et al.Patterns of distant failure by intrinsic breast cancer subtype in premenopausal women treated with neoadjuvant chemotherapy[J].Clin Breast Cancer,2018,18(5):1077-1085.
10 Yang SX,Polley EC.Systemic treatment and radiotherapy,breast cancer subtypes,and survival after long-term clinical follow-up[J].Breast Cancer Res Treat,2019,175(2):287-295.
11 Alonso-Molero J,Dierssen-Sotos T,Gomez-Acebo I,et al.Quality of life in a cohort of 1078 women diagnosed with breast cancer in spain:7-year follow-up results in the MCC-Spain Study[J].Int J Environ Res Public Health,2020,17(22):8411.
12 Hodorowicz-Zaniewska D,Herman K.Principles of follow-up assessments in patients with breast cancer after radical treatment[J].Pol Przegl Chir,2017,89(3):36-39.
13 Ignatov A,Eggemann H,Burger E,et al.Patterns of breast cancer relapse in accordance to biological subtype[J].J Cancer Res Clin Oncol,2018,144(7):1347-1355.
14 Miyashita H,Cruz C,Malamud S.Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate[J].Breast Cancer Res Treat,2020,182(2):381-388.
15 Laakmann E,Witzel I,Fasching PA,et al.Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials gepar quinto and gepar sixto[J].Breast Cancer Res,2019,21(1):60.
16 Akbari ME,Rohani-Rasaf M,Nafissi N,et al.Effecst of patho-biological factors on the survival of recurrent breast cancer cases[J].Asian Pac J Cancer Prev,2018,19(4):949-953.
17 Puvanesarajah S,Gapstur SM,Patel AV,et al.Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in cancer prevention study-II[J].Breast Cancer Res Treat,2019,177(3):679-689.
18 Bychkovsky BL,Lin NU.Imaging in the evaluation and follow-up of early and advanced breast cancer:When,why,and how often?[J].Breast,2017,31(31):318-324.
19 Henry ML,Niu J,Zhang N,et al.Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients[J].JACC Cardiovasc Imaging,2018,11(8):1084-1093.
20 Jerusalem G,Lancellotti P,Kim S.HER2+ breast cancer treatment and cardiotoxicity:monitoring and management[J].Breast Cancer Res Treat,2019,177(2):237-250.
21 Rachel B,Filipa L,Keith U,et al.Management of cardiovascular disease in women with breast cancer[J].Circulation,2019,139(8):1110-1120.
22 Li J,Liu L,Feng Z,et al.Tumor markers CA15-3,CA125,CEA and breast cancer survival by molecular subtype:a cohort study[J].Breast Cancer,2020,27(4):621-630.
23 Wang W,Xu X,Tian B,et al.The diagnostic value of serum tumor markers CEA,CA19-9,CA125,CA15-3,and TPS in metastatic breast cancer[J].Clin Chim Acta,2017,470(470):51-55.
24 Waks AG,Winer EP.Breast cancer treatment:a review[J].JAMA,2019,321(3):288–300.
25 Hong J,Huang J,Shen L,et al.A prospective,randomized study of toremifene vs.tamoxifen for the treatment of premenopausal breast cancer:safety and genital symptom analysis[J].BMC Cancer,2020,16,20(1):663.
26 Vehmanen L,Sievänen H,Kellokumpu-Lehtinen P,et al.Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients[J].Osteoporos Int,2021,32(3):473-482.
27 Kyriazoglou A,Zagouri F,Fotiou D,et al.Discrepancies of current recommendations in breast cancer follow-up:a systematic review[J].Breast Cancer,2019,26(5):681-686.
28 Borreani C,Alfieri S,Infante G,et al.Aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer:profiles of psychological symptoms and quality of life in different patient clusters[J].Oncology,2021,99(2):84-95.
29 Gegechkori N,Egorova N,Mhango G,et al.Bisphosphonate use and incident cardiovascular events among older breast cancer survivors[J].Breast,2019,47:28-32.
30 Cho H,Lee S,Sim SH,et al.Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients[J].Breast Cancer Res Treat,2020,182(2):333-343.
31 Kim H,Chung WB,Cho KI,et al.Diagnosis,treatment,and prevention of cardiovascular toxicity related to anti-Cancer treatment in clinical practice:an opinion paper from the working group on cardio-oncology of the Korean society of echocardiography[J].Cardiovasc Ultrasound,2018,26(1):1-25.
32 Nicolazzi MA,Carnicelli A,Fuorlo M,et al.Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer[J].Eur Rev Med Pharmacol Sci,2018,22(7):2175.
33 Li Z,Tu Y,Wu Q,et al.Clinical characteristics and outcomes of single versus double hormone receptor-positive breast cancer in 2 large databases[J].Clin Breast Cancer,2020,20(2):151-163.
34 Awan A,Esfahani K.Endocrine therapy for breast cancer in the primary care setting[J].Curr Oncol,2018,25(4):285-291.
35 Spronk I,Schellevis FG,Burgers JS,et al.Incidence of isolated local breast cancer recurrence and contralateral breast cancer:a systematic review[J].Breast,2018,39:70-79.

[1]	陈嘉一, 白彦灵. 乳腺癌患者体重指数及体位固定方式对保乳术后调强放射治疗摆位误差的影响[J]. 实用肿瘤学杂志, 2022, 36(4): 327-331.
[2]	宗禹萱, 庞达. 热休克蛋白90在乳腺癌发生发展及治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 381-385.
[3]	杨子涵, 许守平, 庞达. 乳腺癌发生腋窝外三角组织转移特点与影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(3): 226-232.
[4]	何伟丹, 李志高. FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后[J]. 实用肿瘤学杂志, 2022, 36(3): 233-238.
[5]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[6]	杨姝娅, 刘文慧, 骆耐香. UCA1在乳腺癌中的研究现状和应用展望[J]. 实用肿瘤学杂志, 2022, 36(3): 263-267.
[7]	刘婉莹, 庞达. 乳腺浸润性微乳头状癌转移机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 268-272.
[8]	孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.
[9]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[10]	陈赫, 王秋程, 程文. 自动乳腺超声诊断系统在乳腺癌方面的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 193-196.
[11]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.
[12]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[13]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[14]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[15]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.